Change in Expression of Survivin Caused by Using Oxaliplatin in HCT116 Colon Cancer Cells.
10.3393/jksc.2010.26.4.246
- Author:
Won Jun SOHN
1
;
Jung Won LEE
;
Dong Guk PARK
Author Information
1. Department of Surgery, Dankook University School of Medicine, Cheonan, Korea. dkpark@dankook.ac.kr
- Publication Type:Original Article
- Keywords:
Oxaliplatin;
Survivin;
Colorectal cancer;
Mitosis;
Microtubule
- MeSH:
Apoptosis;
Blotting, Western;
Bone Marrow;
Cisplatin;
Colon;
Colonic Neoplasms;
Colorectal Neoplasms;
Cytoplasm;
Immunohistochemistry;
Microtubules;
Mitosis;
Organoplatinum Compounds;
Platinum;
RNA, Messenger
- From:Journal of the Korean Society of Coloproctology
2010;26(4):246-253
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Oxaliplatin is a third-generation platinum compound, and it has no nephrotoxicity and has reduced bone marrow toxicity. Cancer cells that are resistant to cisplatin are sensitive to oxaliplatin. Oxaliplatin is used widely for the treatment of colon cancers. Recently, oxaliplatin was reported to inhibit the expression of survivin, which protects cell apoptosis. However, there are no reports on the expressions of survivin variants and the changes in intracellular localization of survivin in cancer cells. We studied the expression of survivin caused by oxaliplatin in HCT116 colon cancer cells, and we observed the localization of survivin in the mitotic phase. METHODS: We treated the HCT116 colon cancer cells with 2.0 micrometer of oxaliplatin, and we studied the expressions of survivin protein, and survivin mRNA variants, as well as the changes in intracellular localization, by using the Western blot method, RT-PCR, immunocytochemistry, and flowcytometry. RESULTS: Oxaliplatin inhibits the expression of the survivin protein and survivin mRNA in HCT116 colon cancer cells. The expression of the survivin-2B variants, which have no antiapoptotic activity but control cell mitosis by localization on a microtubule, is reduced continuously 2 days after treatment with oxaliplatin. In immunocytochemistry, expression of survivin in the cytoplasm is reduced and especially is not expressed in microtubules and contractile rings. CONCLUSION: One of the mechanisms of oxaliplatin is to inhibit the expression of and to change the localization of survivin. Based on these results, we suggest that changes in the expression of survivin variants and in their localization are two effects of oxaliplatin.
